Savara Inc SVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Savara Announces New Employment Inducement Grant
-
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
-
Savara to Host Analyst and Investor Webinar on September 30, 2024
-
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
-
Savara Announces New Employment Inducement Grant
-
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
Savara Announces New Employment Inducement Grant
Trading Information
- Previous Close Price
- $4.24
- Day Range
- $4.20–4.33
- 52-Week Range
- $3.12–5.70
- Bid/Ask
- $4.23 / $4.24
- Market Cap
- $697.91 Mil
- Volume/Avg
- 753,054 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
- Website
- https://www.savarapharma.com
Comparables
Valuation
|
Metric
|
SVRA
|
CORT
|
VKTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 54.23 | — |
Price/Book Value | 5.76 | 7.69 | 7.41 |
Price/Sales | — | 8.54 | — |
Price/Cash Flow | — | 35.76 | — |
Price/Earnings
SVRA
CORT
VKTX
Financial Strength
|
Metric
|
SVRA
|
CORT
|
VKTX
|
|---|---|---|---|
Quick Ratio | 10.86 | 5.23 | 37.55 |
Current Ratio | 11.31 | 5.57 | 37.69 |
Interest Coverage | — | — | — |
Quick Ratio
SVRA
CORT
VKTX
Profitability
|
Metric
|
SVRA
|
CORT
|
VKTX
|
|---|---|---|---|
Return on Assets (Normalized) | −43.96% | 27.60% | −11.92% |
Return on Equity (Normalized) | −57.12% | 33.89% | −12.36% |
Return on Invested Capital (Normalized) | −50.46% | 30.18% | −17.06% |
Return on Assets
SVRA
CORT
VKTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wwrvrcrhr | Lls | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mxvbxwpq | Cwkql | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xzgxnlq | Krrzgh | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nmsvqvr | Rpjmg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Lvrdmxmn | Rsjl | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pytjwtzy | Rlxng | $28.1 Bil | |||
| Moderna Inc
MRNA
| Xpqfyzbdw | Crjd | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bbkmdlrnf | Zjgz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xfdvgqdz | Qbdpyp | $13.4 Bil | |||
| Incyte Corp
INCY
| Nswtmxnk | Vspjp | $12.7 Bil |
United States